{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TLX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":25.69,"timestamp":1744870320000,"preClose":25.87,"halted":0,"volume":840504,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":274875510,"shares":337878497,"eps":0.1446,"marketStatus":"Not Yet Opened","change":-0.18,"latestTime":"04-17 16:12:00 AEST","open":25.74,"high":25.89,"low":25.45,"amount":21566308,"amplitude":0.017008,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.1446,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":25.87,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":0.6634394430622874,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":274875510,"roa":"5.33%","roe":"13.92%","lyrEps":0.150709,"volumeRatio":0.6634394430622874,"shares":337878497,"dividePrice":0,"high":25.89,"amplitude":0.017008,"preClose":25.87,"low":25.45,"week52Low":13.46,"pbRate":"15.28","psRate":"11.08","week52High":31.97,"institutionHeld":0,"latestPrice":25.69,"eps":0.1446,"divideRate":0,"volume":840504,"delay":0,"ttmEps":0.1446,"open":25.74,"prevYearClose":24.61,"prevWeekClose":25.69,"prevMonthClose":26.52,"prevQuarterClose":26.52,"fiveDayClose":26.58,"twentyDayClose":27.8,"sixtyDayClose":26.84},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TLX.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2527825540","title":"Telix Pharmaceuticals' Potential Brain Cancer Treatment Shows 'Encouraging' Preliminary Results in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527825540","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527825540?lang=en_us&edition=fundamental","pubTime":"2025-04-16 15:32","pubTimestamp":1744788751,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Tuesday it received \"encouraging\" preliminary results from an eight-patient phase 2 study of TLX101 in combination with radiation therapy as a potential treatment for recurrent high-grade glioma, a form of brain cancer.The company said the study showed a median overall survival of 12.4 months for patients treated with the TLX101-radiation therapy combo compared with 9.9 months for patients treated with radiation alone.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK7067","TLX","TLX.AU"],"gpt_icon":0},{"id":"2527402798","title":"Telix Reports No Serious Adverse Events Reported in Brain Cancer Combination Therapy Candidate Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527402798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527402798?lang=en_us&edition=fundamental","pubTime":"2025-04-16 09:55","pubTimestamp":1744768556,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said that its Phase 2 IPAX-Linz study of drug candidate TLX101, in combination with external beam radiation therapy , was well tolerated and showed no serious adverse events in patients with brain cancer, according to a Wednesday filing with the Australian bourse.The study indicated a median overall survival of 12.4 months from treatment initiation, and 32.2 months from diagnosis, the company said.The company has submitted an ethics approval request for a registration-enabling study of TLX101 in recurrent brain cancer, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2527419474","title":"Telix Pharmaceuticals' Prostate Cancer Imaging Agent Illuccix Gets Marketing Authorization in Sweden","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419474","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527419474?lang=en_us&edition=fundamental","pubTime":"2025-04-15 23:23","pubTimestamp":1744730601,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said Tuesday its prostate cancer imaging agent Illuccix has received marketing authorization from Sweden's Medical Products Agency.This approval came after recent authorizations in Norway and Denmark, the company said.Price: 16.86, Change: +0.03, Percent Change: +0.15","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK7067","BK4139","TLX.AU"],"gpt_icon":0},{"id":"2527448763","title":"5 top ASX 200 stocks that brokers rate as buys after the market selloff","url":"https://stock-news.laohu8.com/highlight/detail?id=2527448763","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527448763?lang=en_us&edition=fundamental","pubTime":"2025-04-15 15:10","pubTimestamp":1744701034,"startTime":"0","endTime":"0","summary":"If you are on the lookout for some investment ideas, then it could be worth checking out what analysts saying. Listed below are five ASX 200 stocks that leading brokers currently rate as buy. Here's w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/15/5-top-asx-200-stocks-that-brokers-rate-as-buys-after-the-market-selloff/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7044","JHX.AU","BK7511","RMD.AU","BK7007","TLX.AU","BK7503","BK7016","XRO.AU","BK7067","BK7501","BK7046","MQG.AU","WTC.AU"],"gpt_icon":1}],"pageSize":4,"totalPage":50,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null},{"date":"2023-08-23","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692748800000,"name":null,"time":"","dateTimestamp":1692712800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[]}}